Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 17, 04 December 2023
Open
Access | Article
Application of CRISPR/Cas9 technology in tumor targeted therapy
* Author to whom correspondence should be addressed.
Abstract
Cancer has always been one of the major diseases affecting human health, which is characterized by genomic instability, high individual heterogeneity and inhibitory tumor microenvironment. Epidemiological studies have found that the standardized rates of various new malignant tumors have increased significantly in recent years, while the traditional therapeutic methods are easy to cause serious tissue damages, high recurrence rate and other postoperative complications. CRISPR/Cas9 system is a defense mechanism of archaea. It can recognize and integrate invasive DNA into its own genome through three steps: acquisition, expression and interference. When invaded by the same antigen, it can quickly recognize foreign DNA and specifically cut it, thus playing an immune defense role. This biological mechanism was originally mainly used for gene function identification. With the rapid development and interdisciplinary integration of immunology, genomics and clinical medicine, more and more studies have found that CRISPR/Cas9 system combined with targeted therapy can assist immunotherapy, gene therapy and target screening at the genetic and molecular levels, and has high editing efficiency, which has great prospects in the field of tumor treatment. Therefore, the objective of this review is to explore the application of CRISPR/Cas9 technology in adoptive immune cell therapy, tumor gene therapy and targeted gene screening, so as to provide reference for its efficient application in tumor targeted therapy.
Keywords
CRISPR/Cas9, Tumor, Targeted Therapy
References
1. Huilin S, Yuefang Y and Degang C 2014 Effects of small interfering rna on the proliferation of lung cancer cell a549 and esophageal cancer cell ec109 by inhibiting pokemon expression A. Chinese Pharmacist 17 362-366
2. Yuanyuan Z and Zemin Z 2020 The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications J. Cell Mol Immunol 17 807-21
3. Dandan Z, Ping H, Han X and Li D 2023 Based on real world clinical data of malignant tumor epidemiology study J. Journal of medicine 46-48 493-497
4. Lu Qing Z 2021 Epidemiological analysis of inpatients with malignant tumors in a tertiary traditional chinese medicine hospital from 2017 to 2021 J. Chin J Hospital Statistics 29 448-453
5. Hongxia W, Mingqiang L, Ciaran M Lee, Syandan C, Haewon K, Gang B and Kam W L 2017 Crispr/cas9-based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery ACS. Chem Rev 117 9874-9906
6. Sophia H, Lyndal A and Selvan P 2022 Metastatic ovarian disease following surgical management of grade 1 endometrial endometrioid adenocarcinoma confined to the endometrium, a case report and review of the literature J. Gynecologic Oncology Reports 43 101061
7. Xiaojie Z, Chongyuan S, Zefeng L, Tongbo W, Lulu Z, Penghui N, Chunguang G, Xu C, Yingtai C and Dongbing Z 2022 Long-term survival and pattern of recurrence in ampullary adenocarcinoma patients after curative whipple’s resection: a retrospective cohort study in the national cancer center in china A. American journal of cancer research 12 4062-4073
8. Marie Patrice H, Linda Njonkam T, Samuel Ekane N, Hermine Fouda E, Gregory Halle E and Eugene Belley P 2023 The profile of patients with obstructive uropathy in cameroon: case of the douala general hospital pamj. Pan African Medical Jurnal 67 8170
9. Hideki T, Shinsuke A, Rikiya N, Naohito Y, Yoshitaka K and Nobuyuki M 2022 Investigation of the association between breast cancer-related lymphedema and the side effects of taxane-based chemotherapy using indocyanine green lymphography lrb. Lymphatic research and biology 20 612-617
10. Fei G 2011 Target drug therapy J. J Clin Electrocardiol 20 236
11. YaMin C 2020 Construction of cd105-targeting car-γδ t cells and in vitro functional verification D. Guangxi: Guangxi Medical University
12. van der Oost J, Edze R W, Ryan N J and Blake W 2014 Unravelling the structural and mechanistic basis of cripsr–cas systems Z. Nat Rev Microbiol 12 479-492
13. Martin J, Krzysztof C, Ines F, Michael H, Jennifer A D and Emmanuelle C 2012 A programmable dual-rna-guided dna endonuclease in adaptive bacterial immunity A. science 337 816-21
14. Jialin T 2023 Whole-tumor markers: a new method for evaluating the efficacy of tumor immunotherapy J. Scientia Sinica 75 20-23+4
15. Hong-yan J, Yan-hui N and XingYan Y 2023 Construction of humanized mouse model of pd-1/pd-L1/c5ar1 gene and its application in immunotherapy J. Central South Pharmacy 21 1763-1768
16. EA G, E G, MM R and SA R 1982 The lymphokine-activated killer cell phenomenon-invitro and invivo studies J. Cell Immunol 70 409-409
17. Surya M, Samuel T. H, Corinne B, Amin A, Israt S. A, Tara M, Travis M. S, Chirag B. P, Edward E. G, Crystal L. M and Sanjiv S. G 2020 Intravital imaging reveals synergistic effect of car t-cells and radiation therapy in a preclinical immunocompetent glioblastoma model A. Onco-immunology 9 1757360
18. Rachel C. L, Evan W. W, Elena S, David G, Peng X, Zinaida G, Hima A, John L, Robert J, Victor T, Surya N, Jeffrey G, Charles F. A. de B, Robbie M, Ansuman T. S, Stephen R. Q, Michelleet M, Howard Y. C and Crystal L. M 2019 c-Jun overex-pression in car t cells induces exhaustion resistance A. Nature 576 293-300
19. Frederik Holm R, Nanna Pi L, Anna Karina J, Mariane Hogsbjerg S, Saskia K, Ole Schmeltz S, Rasmus O. B and Martin T 2023 Development of hiv-resistant car t cells by crispr/cas-mediated car integration into the ccr5 locus A. Viruses 15 15010202
20. Le C, Ran, F. Ann R, David C, Shuailiang L, Robert B, Naomi H, Patrick D. H, Xuebing W, Wenyan J, Luciano A. M and Feng Z 2013 Multiplex genome engineering using crispr/cas systems. A. Science 339 819-823
21. Jiangtao R, Xuhua Z, Xiaojun L, Chongyun F, Shuguang J, Carl H. J and Yangbing Z 2017 Versatile system for rapid multiplex genome-edited car t cell generation A. Oncotarget 8 17002-17011
22. Wanghong H, Zhenguo Z, Yanling J, Gaoxin L, Kang S, QiLang C, Xiaojing M, Fang W 2019 Crispr/cas9-mediated pd-1 disruption enhances human mesothelin-targeted car t cell effectors functions A. Cancer Immunol Immunother 68 365-377
23. Linlin Z 2021 Effects of CRISPR/ Cas9-mediated gene editing of SHP-1 or PD-1 on anti-tumor ability of CAR T cells D. Nanjing university
24. Giuffrida L, Sek K, Melissa A. H, Junyun L, Amanda X. Y. C, Deborah M, Kirsten L. T, Emma V. P, Sherly M, Christina M, Gregory D. S, Benjamin J. S, Ian A. P, Paul J. N, Simon J. H, Lev M. K, Imran G. H, Phillip K. D and Paul A. B 2021 Crispr/cas9 mediated deletion of the adenosine a2a receptor enhances car t cell efficacy A. Nature Communications 12 3236
25. Xuejin O, Qizhi M, Wei Y, Xuelei M and Zhiyao H 2021 Crispr/cas9 gene-editing in cancer immunotherapy: promoting the present revolution in cancer therapy and exploring more J. Frontiers in Cell and Developmental Biology 9 674467
26. Juan F, JiaTaoL and Na Z 2023 Crispr/cas9 knockout of endogenous tcr enhances the killing effect of tcr-t cells on hpv16 positive cervical cancer siha cells J.Chinese Journal of Oncology Biotherapy 30 373-379
27. Sara M, Pietro G, Zulma M, Eliana R, Elisa L, Barbara C, Giulia S, Elena P, Angelo L, Andreas R, Nicoletta C, Martina R, Giacomo O, Giulia E, Monica C, Bernhard G, Antonello S, Anna M, Attilio B, Luca V, Maurilio P, Fabio C, Michael C. H, Luigi N and Chiara B 2017 Ny-eso-1 tcr single edited stem and central memory t cells to treat multiple myeloma without graft-versus-host disease A. blood 130 606-618
28. Aleksandra W, Maxime D, Benjamin B, Samuel A. R, Eun Sook P, El-Ad David A, Anela B, Alessia B, Miriam M, Adeeb H. R and Brian D. B 2018 Protein Barcodes Enable High-Dimensional Single-Cell CRISPR Screens J. Cell 175 1141 - 1155
29. Matthew B. D, Guangchuan W, Ryan D. C, Lupeng Y, Lvyun Z, Xiaoyun D, Jonathan J. P, Hyunu R. K, Youssef E and Christopher D. G 2019 Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells Dong J. Cell 178 1189-1204
30. Zachary S, Pavlovic Z, Megha C, Traver H, Xiaowei W, Xiaoyu Z, Melanie R, Kevin R. B, Sridevi J, Rene O, Sylvia F. B, Jarrett A, James P, Hans C, Sachdev S, Jason M and Stephane A 2017 Genome-wide crispr screens reveal a wnt-fzd5 signaling circuit as a druggable vulnerability of rnf43-mutant pancreatic tumor A. Nat Med 23 60-68
31. Ying H, Geng Q, TingTing C, Chuanqi Z, Jinsong R and Xiaogang Q 2023 A bimetallic nanoplatform for sting activation and crispr/cas mediated depletion of the methionine transporter in cancer cells restores anti-tumor immune responses S. Nat Communications 14 4647
32. Ning W, Chao L, Yingjie L, Dongxue H, Xinyue W, Xiaorong K, Xiye W, Qinjie W and Changyang G 2023 A cooperative nano-crispr scaffold potentiates immunotherapy via activation of tumour-intrinsic pyroptosis S. Nat Communications 14 779
33. Erwei Z, Yidi S, Wu W, Tanglong Y, Wenqin Y, Hao S, Liyun Y, Lars M. S, Yixue L and Hui Y 2019 Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos J. Science 364 289-92
34. Xiaojie X, Tao W, Huhu X, Da L, Hongming P, Jun W and Yuan P 2019 Delivery of crispr/cas9 for therapeutic genome editing J. J Gene Med 21 e3107
35. Danny W, Johanna W and Enrico M 2019 Delivery aspects of crispr/cas for in vivo genome editing J. Acc Chem Res 52 1555-64
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Modern Medicine and Global Health
- ISBN (Print)
- 978-1-83558-197-1
- ISBN (Online)
- 978-1-83558-198-8
- Published Date
- 04 December 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/17/20240655
- Copyright
- 04 December 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited